Testing a single pill for hard-to-control high blood pressure in Brazil
Compares one combined pill with usual care in adults with resistant hypertension.
Plain-language title generated from the registry record
Registry title: Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)
Key facts
- Where
- São Paulo, BrazilSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07259733, who can take part
Where in Brazil
- Instituto Dante Pazzanese de CardiologiaSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Dante Pazzanese de Cardiologia
- Trial code
- NCT07259733
- Record updated
- 2 December 2025
- Original description
This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.Read full original descriptionShow less
Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)
This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.
Inclusion: Treatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB); Recent 24-hour ambulatory blood pressure monitoring (ABPM) (<1 month) showing values above target (24-hour BP ≥130/80 mmHg); Office blood pressure ≥140/90 mmHg; Poor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4); -.
Exclusion: Significant valvular heart disease; Severe psychiatric disorders; History of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache); Reduced left ventricular ejection fraction (LVEF < 55%); Severe renal impairment (creatinine clearance < 30 mL/min or eGFR < 30 mL/min/1.73 m²); Active malignancy with life expectancy < 2 years; Indispensable use of beta-blockers or mineralocorticoid receptor antagonists; Office blood pressure ≥ 220 × 120 mmHg; Atrial fibrillation or atrial flutter; Use of oral anticoagulants; Body mass index (BMI) ≥ 40 kg/m²; Pregnant or breastfeeding women; -.